Nurix Therapeutics, Inc.
NASDAQ:NRIXBiotechnology
Healthcare
$14.10 +0.85%
+$0.15 today
- Market cap
- $1.54B
- Beta
- 1.87
- P/E (TTM)
- -6.4
- EPS (TTM)
- -$2.68
52W Low $8.20High $22.50
Volume 2.79M
Average 1.74M
Balance Sheet
Inspect the capital base behind the business.
Assets
$688.13M
FY 2025 · Annual
+2.8% YoYLiabilities
$149.39M
FY 2025 · Annual
+4.9% YoYEquity
$538.75M
FY 2025 · Annual
+2.2% YoYBalance Sheet
USD
Metric | FY2021 Nov 2021 | FY2022 Nov 2022 | FY2023 Nov 2023 | FY2024 Nov 2024 | FY2025 Nov 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 80.51M | 64.47M | 54.63M | 110M | 246.96M |
| Short-term Investments | 215.21M | 244.67M | 233.28M | 499.59M | 345.98M |
| Net Receivables | 6.2M | 1.1M | 800K | 1.5M | 0 |
| Inventory | 0 | (1.1M) | 0 | 0 | 0 |
| Other Current Assets | 900K | 9.31M | 6.8M | 8.3M | 13.88M |
| Total Current Assets | 311.12M | 318.45M | 295.5M | 619.39M | 606.82M |
| Property, Plant & Equipment (Net) | 25.35M | 29.51M | 47.95M | 45.9M | 73.01M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 137.48M | 63.88M | 7.42M | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 3.12M | 4.92M | 4.72M | 4.06M | 8.31M |
| Total Non-current Assets | 165.65M | 98.31M | 60.1M | 49.96M | 81.32M |
| Total Assets | 476.77M | 416.76M | 355.6M | 669.34M | 688.14M |
| Account Payables | 6.65M | 5.06M | 6.4M | 11.48M | 11.22M |
| Short-term Debt | 3.85M | 5.53M | 7.49M | 0 | 0 |
| Tax Payables | 75K | 85K | 30K | 1.24M | 0 |
| Deferred Revenue | 41.21M | 37.63M | 48.1M | 38.36M | 17.58M |
| Other Current Liabilities | 5.67M | 9.14M | 751K | 18.91M | 23.64M |
| Total Current Liabilities | 66.26M | 70.66M | 86.96M | 95.85M | 86.47M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 59.02M | 35.97M | 45.02M | 26.21M | 10.01M |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 68.21M | 42.41M | 68.15M | 46.5M | 62.92M |
| Total Liabilities | 134.47M | 113.06M | 155.11M | 142.35M | 149.39M |
| Common Stock | 45K | 47K | 49K | 76K | 102K |
| Retained Earnings | (220.89M) | (401.25M) | (545.2M) | (738.77M) | (1B) |
| Accumulated OCI | (608K) | (4.32M) | (655K) | 150K | 105K |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 342.3M | 303.7M | 200.49M | 526.99M | 538.75M |
| Total Debt | 13.04M | 11.96M | 30.61M | 28.3M | 55.73M |
| Net Debt | (67.47M) | (52.51M) | (24.01M) | (81.69M) | (191.23M) |
Balance Sheet
Assets, liabilities & equity
| Cash & Equivalents | $720.2M |
| Short-term Investments | $328.0M |
| Receivables | $20.0M |
| Other Current | $35.4M |
| Total Current Assets | $1.1B |
| PP&E (Net) | $68.0M |
| Long-term Investments | $14.8M |
| Other Non-current | $8.7M |
| Total Non-current Assets | $91.6M |
| Total Assets | $1.2B |
Analysis
Selected assets total $1.2B for Latest. The largest visible component is Cash & Equivalents at $720.2M, about 60.3% of the tab total. Use the mix to judge balance sheet concentration, liquidity, leverage, and how much of book value is supported by tangible operating assets.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 4, 2026 | |
| 8-K | Current report | Nov 3, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 2, 2026 |
How much cash does NRIX have?
Nurix Therapeutics, Inc. (NRIX) reported $246.96M in cash and equivalents in fiscal 2025.
How much debt does NRIX carry?
Nurix Therapeutics, Inc. (NRIX) reported $55.73M of total debt, with net debt of -$191.23M.
Continue the stock analysis
Jump to another research area for this company.